产品
编 号：F134962
分子式：C24H17ClF3NO4
分子量：475.84
分子式：C24H17ClF3NO4
分子量：475.84
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1354745-52-0
产品详情
生物活性：
ELQ-300 is a potent and orally bioavailable antimalarial agent, acts as an inhibitor of the reductive (Qi) site of the cytochrome bc1 complex (cyt bc1). ELQ-300 inhibits growth of P. falciparum Dd2, Tm90-C2B, and D1 with IC50 values of 6.6, 4.6 and 160 nM, respectively. ELQ-300 can be used for the research of antimalarial.
体内研究：
ELQ-300 (1 and 10 mg/kg; p.o. once daily for 1 or 4 days) inhibits P. yoelii growth in an acute infection model.ELQ-300 (10 and 20 mg/kg; p.o. once daily for 1 or 4 days) prevents recurrence of infection in mice.Animal Model:6-week female CF-1 mice with P. yoelii-WT infection
Dosage:1 and 10 mg/kg
Administration:Oral gavage; 1 mg/kg once daily for 4-day; 10 mg/kg once daily for 1-day
Result:Inhibited P. yoelii with ED50 values of 0.04 and 0.03 mg/kg for 4-day dosing and 1-day dosing, respectively.
Animal Model:6-week female CF-1 mice with P. yoelii-WT infection
Dosage:10 and 20 mg/kg
Administration:Oral gavage; 10 mg/kg once daily for 4-day; 20 mg/kg once daily for 1-day
Result:Effectively prevented recrudescence in the 4-day dosing studies with infection mice.
体外研究：
ELQ-300 (0-70 nM, 21 d) inhibits P. falciparum Dd2, Tm90-C2B, and D1 growth with IC50 values of 6.6, 4.6 and 160 nM, respectively.
ELQ-300 is a potent and orally bioavailable antimalarial agent, acts as an inhibitor of the reductive (Qi) site of the cytochrome bc1 complex (cyt bc1). ELQ-300 inhibits growth of P. falciparum Dd2, Tm90-C2B, and D1 with IC50 values of 6.6, 4.6 and 160 nM, respectively. ELQ-300 can be used for the research of antimalarial.
体内研究：
ELQ-300 (1 and 10 mg/kg; p.o. once daily for 1 or 4 days) inhibits P. yoelii growth in an acute infection model.ELQ-300 (10 and 20 mg/kg; p.o. once daily for 1 or 4 days) prevents recurrence of infection in mice.Animal Model:6-week female CF-1 mice with P. yoelii-WT infection
Dosage:1 and 10 mg/kg
Administration:Oral gavage; 1 mg/kg once daily for 4-day; 10 mg/kg once daily for 1-day
Result:Inhibited P. yoelii with ED50 values of 0.04 and 0.03 mg/kg for 4-day dosing and 1-day dosing, respectively.
Animal Model:6-week female CF-1 mice with P. yoelii-WT infection
Dosage:10 and 20 mg/kg
Administration:Oral gavage; 10 mg/kg once daily for 4-day; 20 mg/kg once daily for 1-day
Result:Effectively prevented recrudescence in the 4-day dosing studies with infection mice.
体外研究：
ELQ-300 (0-70 nM, 21 d) inhibits P. falciparum Dd2, Tm90-C2B, and D1 growth with IC50 values of 6.6, 4.6 and 160 nM, respectively.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备